Stock Events

Stock Events

Ondine Biomedical

$0.17

5

+$0+0% Friday 21:00

Statistics

Day High

0.17

Day Low

0.17

52W High

0.17

52W Low

0.14

Volume

40,000

Avg. Volume

0

Mkt Cap

75.38M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

25FebExpected

Q2 2023

Q1 2024

Q2 2024

Q4 2024

Q1 2025

Q2 2025

Q4 2025

999

333

-333

-999

Expected EPS

N/A

Actual EPS

N/A

Financials

-931.74%Profit Margin

Unprofitable

2019

2020

2021

2022

2023

2024

2.88MRevenue

-26.83MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OBIMF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

AbbVie operates in the pharmaceuticals sector, focusing on immunology and oncology, areas that overlap with Ondine's antimicrobial photodynamic therapy.

Johnson & Johnson

Johnson & Johnson, through its pharmaceutical division, competes in developing treatments that could potentially overlap with Ondine's infection prevention solutions.

Pfizer is involved in the development and commercialization of vaccines and drugs, including those for infections, directly competing with Ondine's focus.

Merck is known for its strong focus on infectious diseases, directly competing with Ondine's antimicrobial therapies.

Gilead Sciences

Gilead Sciences focuses on antiviral drugs, which could be seen as alternative treatments to Ondine's photodynamic therapies for infections.

Bristol-Myers Squibb

Bristol Myers Squibb engages in biopharmaceuticals, competing in the space of innovative treatments for various diseases, including those targeted by Ondine.

Amgen focuses on human therapeutics, with a broad portfolio that could compete with Ondine's therapies in certain therapeutic areas.

Novartis focuses on a wide range of healthcare areas, including treatments for diseases that Ondine's technology targets.

AstraZeneca operates in several therapeutic areas, including infections, directly competing with Ondine's infection prevention and treatment technologies.

Sanofi focuses on healthcare solutions across a broad range of areas, including infectious diseases, making it a competitor to Ondine's technologies.

About

Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, and sinus; and serious and chronic wounds, chronic sinusitis, ventilator-associated pneumonia VAP, and central line bloodstream infections, as well as catheter-associated urinary tract infection. Ondine Biomedical Inc. was incorporated in 1996 and is headquartered in Vancouver, Canada.

Show more...

CEO

Country

US

ISIN

CA68234M2058

Listings

0 Comments

Share your thoughts

FAQ

What is Ondine Biomedical stock price today?▼

The current price of OBIMF is $0.17 USD — it has increased by +0% in the past 24 hours. Watch Ondine Biomedical stock price performance more closely on the chart.

What is Ondine Biomedical stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Ondine Biomedical stocks are traded under the ticker OBIMF.

What is Ondine Biomedical market cap?▼

Today Ondine Biomedical has the market capitalization of 75.38M

When is the next Ondine Biomedical earnings date?▼

Ondine Biomedical is going to release the next earnings report on September 29, 2026.

What is Ondine Biomedical revenue for the last year?▼

Ondine Biomedical revenue for the last year amounts to 2.88M USD.

What is Ondine Biomedical net income for the last year?▼

OBIMF net income for the last year is -26.83M USD.

When did Ondine Biomedical complete a stock split?▼

Ondine Biomedical has not had any recent stock splits.